Remdesivir: A beacon of hope from Ebola virus disease to COVID‐19. (30th July 2020)

• Record Type: Journal Article
• Authors: Nili, Ali; Farbod, Abolfazl; Neishabouri, Afarin; Mozafarihashjin, Mohammad; Tavakolpour, Soheil; Mahmoudi, Hamidreza
• Is Part Of: Reviews in medical virology. Volume 30:Number 6(2020)
• Page Start: 1
• Page End: 13
• Publication Date: 2020-07-30
• Subjects: coronavirus -- COVID‐19 -- emergency use authorization -- GS‐441524 -- remdesivir -- SARS‐CoV‐2; Medical virology -- Periodicals; Review Literature -- Periodicals; Virus Diseases -- Periodicals; Viruses -- Periodicals; 616.0194
• DOI: 10.1002/rmv.2133
• Languages: English
• ISSNs: 1052-9276

Abstract

Summary: Since the emergence of coronavirus disease 2019 (Covid‐19), many studies have been performed to characterize severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and find the optimum way to combat this virus. After suggestions and assessments of several therapeutic options, remdesivir (GS‐5734), a direct‐acting antiviral drug previously tested against Ebola virus disease, was found to be moderately effective and probably safe for inhibiting SARS‐CoV‐2 replication. Finally, on 1 May 2020, remdesivir (GS‐5734) was granted emergency use authorization as an investigational drug for the treatment of Covid‐19 by the Food and Drug Administration. However, without a doubt, there are challenging days ahead. Here, we provide a review of the latest findings (based on preprints, post‐prints, and news releases in scientific websites) related to remdesivir efficacy and safety for the treatment of Covid‐19, along with covering remdesivir history from bench‐to‐bedside, as well as an overview of its mechanism of action. In addition, active clinical trials, as well as challenging issues related to the future of remdesivir in Covid‐19, are covered. Up to the date of writing this review (19 May 2020), there is one finished randomized clinical trial and two completed non‐randomized studies, in addition to some ongoing studies, including three observational studies, two expanded access studies, and seven active clinical trials registered on the clinicaltrials.gov and isrctn.com websites. Based on these studies, it seems that remdesivir could be an effective and probably safe treatment option for Covid‐19. However, more randomized controlled studies are required.